Interactions between peptides and sera.

<p>A. SPRi kinetic curves of serum and peptides immobilized on the surface of a prism. Changes in % reflectivity were measured as a function of time. Each curve shows binding to one of the peptides. B. SPRi difference images of the prism surface at different times. Peptide solutions at 10 mg/mL were spotted on the biochip surface. Difference images show the surface at the start of injection, during the injection and at the stop of injection. C. Number of effective interactions between the 39 peptides covering the sequence of hnRNP B1 and sera from healthy donors, autoimmune hepatitis (AIH), systemic lupus erytheamtosus (SLE), rheumatoid arthritis (RA) patients.</p

Comparisons of apparent k_off (s^-1)values.

<p>A. Between groups of patients and donors. Each group of patients was compared with a group of healthy donors. Complexes between AIH (autoimmune hepatitis) sera and peptide P7 (AA_55-70) were more stable than with healthy control sera. Conversely, complexes between donor sera and peptides P14 (AA_118-133) and P30 (AA_262-277) were more stable than with SLE (systemic lupus erytheamtosus) sera. The same applied to peptide P17 (AA_145-160) and RA (rheumatoid arthritis) sera. B. Between groups of patients. Complexes between AIH sera, peptides P6 (AA_46-61) /P7 (AA_55-70) and P30 (AA_262-277) were more stable than those formed respectively by RA and SLE sera. SLE sera also formed complexes less stable than RA sera with peptides P14 (AA_118-133), P20 (AA_172-187), P39 (AA_340-353). </p

Anti IgM binding to material from serum retained at immobilised peptide P7 in the presence and absence of nucleases.

<p>Sera were passed across immobilised peptides and the resulting complexes were allowed to dissociate so that only the most stable complexes remained. Anti-IgM was then flowed across the surfaces. The experiment was repeated after pre-treatment with, and in the presence of, nucleases as described in Materials and Methods. A. P7 Binding curves for AIH (autoimmune hepatitis), RA (rheumatoid arthritis) and SLE (systemic lupus erytheamtosus) sera binding to immobilised P7 and subsequent binding of anti-IgM antibodies in the presence or absence of nucleases. B. P7 Binding curves for donor sera binding to immobilised P7 and subsequent binding of anti-IgM antibodies in the presence or absence of nucleases. </p

Hematological adverse events and their management during triple therapy after liver transplantation.

<p>Abbreviations: EPO: erythropoietin; Hb: hemoglobin level; NC: neutrophil count; ns: non significant; PC: platelet count; PEG-IFN: pegylated interferon; RBV: ribavirin; W: week</p><p>Hematological adverse events and their management during triple therapy after liver transplantation.</p

Mean estimated glomerular filtration rates during triple therapy.

<p>The median decrease of eGFR was 7.68mL/min with BOC and 8.53mL/min with TVR (<i>P</i> = ns). Seven patients were hospitalized because of acute kidney failure, six of whom were in the TVR group. No CNI overdoses were observed and all patients recovered after a saline infusion.</p

Virological responses during triple therapy after liver transplantation.

<p>An early virological response (EVR) was observed when the HCV viral load was undetectable at week 12. An extended virological response meant negative HCV RNA at week 4 and week 12. An EOT (end of treatment response) was achieved when HCV RNA was undetectable at 48 weeks. SVR12 and SVR 24 were defined as undetectable HCV RNA at 12 and 24 weeks after the discontinuation of antiviral therapy, respectively. Five patients discontinued triple therapy (three with TVR and two with BOC) before week 48 with undetectable HCV RNA and still achieved an SVR12 and SVR24.</p

Description of immunosuppressive therapy management.

<p>Abbreviations: CNI: calcineurin inhibitors; IS: immunosuppression; n: number; sd: standard deviation; MMF: mycophenolate mofetil; PI: protease inhibitors</p><p>Description of immunosuppressive therapy management.</p

Baseline characteristics of the study population.

<p>Abbreviations: HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; M: male; n: number; PEG-IFN: pegylated interferon</p><p>Continuous variables are expressed as mean ± standard deviation.</p